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In  the  majority  of  chronic  lymphocytic  leukemias  (CLL),  proliferative  B 
lymphocytes are  thought to be frozen in  vivo at a  given maturation  stage  (1). 
Recently,  several  studies  have  emphasized  that  CLL  cells  could  be  driven  to 
differentiate  into  plasma  cells  in  vitro  (with  or  without  proliferation)  upon 
triggering  by  mitogens  (2,  3,  4)  or  T  cell-derived  factors  (5,  6).  Thus  far, 
however, no study has been designed to elucidate whether leukemic B cells can 
be triggered by T  cell-derived iymphokines that are known to induce normal B 
cells to proliferate. In preliminary experiments, we found that leukemic B cells 
from six of nine CLL patients, when stimulated with anti-~ antibody and/or with 
Staphylococcus aureus Cowan strain I (SAC), proliferate in the presence of various 
T  cell-derived  conditioned  media,  which  potentially  contained  a  number  of 
lymphokines (unpublished  data).  Absorption experiments suggested that inter- 
leukin 2 (IL-2) was a potent growth factor for these leukemic B cells. We report 
here that purified recombinant IL-2 is indeed able to induce leukemic cells from 
some patients to proliferate. These data, obtained with monoclonal populations 
of B cells, which are likely free of contaminating T  cells, provide further evidence 
that IL-2 can trigger activated B cells to proliferate. 
Material and  Methods 
Isolation  and Characterization  of Lymphoid  Cells.  Nine cases of well-documented B cell 
CLL were studied. Mononuclear cells were purified from blood by centrifugation on a 
Ficoll-Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden) density gradient. Although 
the percentage of E-rosetting cells was very low (~<1% except in patient ROS) B cells were 
purified by one or two cycles of depletion by Ficoll-Hypaque centrifugation of those cells 
forming E rosettes with 2 aminoethylisothiouronium bromide-treated sheep red blood 
cells. Cell marker studies showed that >99% of the cells were monoclonal B cells bearing 
surface IgM and IgD in eight cases, and IgG in one. 
Normal B cells were purified from the spleen of a patient with idiopathic thrombocy- 
topenic purpura. This B cell population contained <1% T  cells and >95% surface Ig- 
positive cells. 
Monoclonal antibodies (mAb) against B cells (against B 1 antigens), IL-2 receptor (TAC), 
and E-rosette receptor (D66 and OKT11) were kind gifts of Dr. S. F. Schlossman and L. 
E.  Nadler  (Dana-Farber  Cancer  Institute,  Boston,  MA),  T.  A.  Waldmann  (National 
O.  Lantz is recipient of a fellowship from the Foundation pour la Recherche M~dicale and  the 
Ministbre de la Recherche et de I'Industrie. 
J. ExP. MEn. © The Rockefeller University Press • 0022-1007/85/05/1225/06 $1.00  1225 
Volume 161  May 1985  1225-1230 1226  LANTZ  ET  AL.  BRIEF  DEFINITIVE  REPORT 
Institutes of Health, Bethesda, MD), and L. Boumsell (INSERM U93). OKT3 was obtained 
from Ortho Pharmaceutical, Raritan, NJ. 
Sources oflL-2.  Semipurified IL-2 was prepared from phytohemagglutinin-stimulated 
peripheral blood mononuclear cell supernatants, precipitated by ammonium sulfate, and 
recovered  after  gel  filtration  on  ultrogel  AcA  54  (Industrie  Biologique  de  France, 
Villeneuve la  Garenne,  France).  Purified  recombinant IL-2 (with an estimated specific 
activity of 107 U/mg protein) was obtained from Biogen S.A. (Geneva, Switzerland). This 
preparation contained 97.3% recombinant IL-2. 
Microassay  for  IL-2  activity  determination  was  performed  on  the  IL-2-dependent 
murine cell line, CTLL, according to Gillis et ai. (7). We define one unit of IL-2 as the 
activity  contained  in  a  sample  dilution  yielding  a  proliferation  equal  to  50%  of the 
maximum [3H]thymidine uptake (in  cpm) of the first French  Workshop standard  IL-2 
preparation (8).  In these conditions, semipurified and recombinant IL-2 had an activity 
of 14 and 1,900 U/ml, respectively. Therefore, 1 U corresponds to 10.5 ng recombinant 
IL-2. One U  IL-2 contained <0.05 pg endotoxin, as assessed by the limulus amebocyte 
assay. 
Assay of B Cell Proliferation.  Proliferation was determined after preactivation of B cell 
by SAC or anti-# antibody. In the SAC assay (9), cells were cultivated at a concentration 
of 106/ml for 3 d in 250-ml flasks (1-53373, Nunc, Roskilde, Denmark), with or without 
SAC (1 : 10,000 vol/vol). SAC was prepared in our laboratory (killed by incubation in 1.5% 
formaldehyde, followed by heat treatment). This preparation has no mitogenic activity 
on purified T  cells. At day 3 (unless otherwise specified) cells were washed three times in 
complete medium, and distributed at a cell concentration of 105 or 5 X 104 cells/well in 
200 #1 medium, in 96-well, flat-bottom microtiter plates (67008, Nunc) with serial dilutions 
of purified recombinant IL-2 for three additional days. 
In the costimulatory assay with anti-# antibody (10), a mouse IgG1 mAb against human 
#  chains  (prepared  in  our  laboratory) was  coupled  to  Sepharose  CL  4  B  (2  mg/ml) 
(Pharmacia Fine Chemicals) and used at a concentration of 1 #g/ml; this dose was selected 
on the basis of preliminary experiments on normal and leukemic B cells.  10 h leukemic, or 
5  ×  104 normal  B  cells  were incubated  in  200  #1  medium in  microtiter plates,  in  the 
presence or absence of anti-~ antibody, with serial dilutions of IL-2 to be tested, for 3 or 
6d. 
In  both  assays,  1  #Ci/well  [~H]thymidine  ([~H]TdR)  (Commisariat  pour  l'Energie 
Atomique, Gif-sur-Yvette, France) was added during the last 18 h of culture. Cells were 
thereafter harvested on glass fiber filters, and incorporation of [3H]TdR was measured 
by standard liquid scintillation counting. 
Results and  Discussion 
The main result of this study is the demonstration  that purified recombinant 
IL-2 is able to trigger leukemic B cells from six of nine CLL cases to proliferate 
after preactivation. The effect of recombinant IL-2 on CLL B cells was assessed 
in two different B cell proliferative assays, i.e. after activation by SAC or anti-#. 
IL-2  at  various  concentrations  (0.01-3  U/ml)  was  added  at  day  0  in  the  co- 
stimulatory assay with anti-#, or at day 3 after preactivation by SAC. In the SAC 
assay, cells from three of nine patients proliferated in response to SAC alone:  in 
two cases (ETA and  ROS) the  response was weak, with a  peak at day 3;  in  the 
third case (BAU), the proliferative response was high, with a peak at day 6. Cells 
that  responded  to  SAC  (from the  aforementioned  three  patients),  proliferated 
in  response  to  IL-2  (Fig.  1).  No  response  was observed among cells  from  the 
other six patients. 
Costimulation  of purified  leukemic  B  cells with  IL-2 and  anti-#  gave only a 
marginal  response  (<1,500  cpm)  at  day  3.  When  the  incubation  time  was 
extended  to 6  d,  a  clearcut pattern  of IL-2 reactivity emerged in  the  leukemic LANTZ  ET  AL.  BRIEF  DEFINITIVE  REPORT  1227 
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FIGURI~  1.  Proliferation of SAC-activated CLL B cells in response to recombinant Ik-2:106 
cells/ml were incubated for 3 d (B, C, and D) or 9 d (A) with (I) or without (0) SAC (1:10,000 
vol/vol), washed three times, and resuspended at  105 (A, C, and D) or 5  x  104 cells/well (B) 
with serial dilutions of recombinant IL-2.  1 #Ci of [3H]TdR was added during the last 18 h of 
the three additional days of culture. The proliferation of cells in the absence of IL-2, with or 
without preactivation by SAC, is shown by the corresponding open symbols (['-l, O). 
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FIGURE 2.  Proliferative response of anti-tL-activated CLL B cells to recombinant IL-2:105 
cells/well were incubated for 6 d  with (I) or without (O) insolubilized anti-# mAb (1 #g/ml), 
and  with  0.01-3  U/ml  recombinant  IL-2.  The  proliferation  of  cells  in  the  absence  of 
recombinant I L-2, with or without anti-~, is shown by the corresponding open symbols (ff], O). 1228  LANTZ  ET  AL.  BRIEF  DEFINITIVE  REPORT 
cells (Fig.  2).  Interestingly,  cells from one patient  (PERI) proliferated  to  IL-2 
alone,  the  response  being  enhanced  after  preactivation  with  anti-t~. The  cells 
from four other patients (ETA, CAR, POU, and BAU) proliferated in response 
to IL-2 when simultaneously activated by anti-t~.  Finally, no response was noted 
in three cases (HER, MEY, and PERO). Cells from patient ROS, which featured 
surface IgG and  which proliferated  in  response to IL-2 after SAC stimulation 
were not studied in this assay. Cells from a single patient proliferated slightly in 
the presence of anti-~ alone; in the other cases, cells were preactivated without 
detectable proliferation,  as actually occurs for normal  B cells triggered by low 
doses of anti-~ (11). Of note, the CLL cell response to IL-2 peaked at day 6, i.e. 
later than the response of anti-t~-activated normal B cells to growth factors (11). 
The amount of IL-2 needed for the leukemic cells to proliferate varied from 
patient  to patient.  In  one case (POU),  the  cells  were responsive only at  high 
concentrations of IL-2 (3 and  1 U/ml), whereas in the other four cases (ETA, 
BAU, PERI, and CAR), the dose/response curves were similar,  with a  peak of 
~1  U/ml, and background-level proliferation at a  concentration  of 0.02  U/ml. 
With regard to these results, it is noteworthy that our IL-2 assay on the murine 
IL-2-dependent CTLL line is able to detect ~0.01  U/ml IL-2. 
The use of leukemic B cells makes it very unlikely that the observed effect was 
due to residual T or accessory cells. After one or two cycles of E-rosette depletion, 
the leukemic population tested was almost pure, i.e. contained >99% surface Ig- 
positive monoclonal cells and <0.02%  T  cells, and <0.01% polyclonal B cells, as 
estimated by cell markers at day 0,  3, and 6  of culture.  On the other hand,  to 
exclude the possibility that  the responsiveness to IL-2 was a  unique feature of 
these leukemic B cells, we performed similar experiments on spleen-enriched B 
cell populations,  Again,  recombinant or semipurified IL-2 induced activated B 
cells to  proliferate  in  a  dose-dependent  fashion  (Fig.  3).  These  results  are  in 
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FIGURE 3.  Proliferative response of SAC-preactivated normal B  cells from spleen to IL-2. 
l0  s cells/ml purified B cells were cultivated for 3 d with SAC (1:10,000 vol/vol), washed, and 
recuhivated at  105  cells/well  for  three  additional  days  with  0.01-2  U/ml  of IL-2,  either 
semipurified (0) (see Materials and Methods), or recombinant (11). Proliferation with medium 
alone is shown by the open symbol (0).  In all cases,  standard deviation was <10%  of the 
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agreement  with  recently  published  data.  IL-2  receptors  have  been  found  on 
~25%  of anti-u-  or  SAC-activated  normal  B  cells  (12,  and  our  unpublished 
results).  Herein,  the  study of IL-2  receptor  expression  by leukemic  cells was 
hampered,  in  some  cases,  by  nonspecific  binding  to  a  strong  Fc  receptor. 
However, fresh cells from two of six patients were weakly stained by anti-TAC; 
in one case, they proliferated in response to IL-2 without preactivation (patient 
PERI), and in the other case (BAU), a second signal, delivered either by SAC or 
anti-u, was needed for proliferation to occur. After activation by SAC or anti-u, 
the cells from two other patients,  although  responsive to IL-2, did not exhibit 
detectable amounts of TAC antigen, possibly because of a low density of receptor. 
Finally,  in  one  case studied,  anti-TAC  was able to  inhibit  recombinant  IL-2- 
induced proliferation of leukemic cells up to a  10  -5 dilution,  providing further 
evidence that IL-2 is indeed the active lymphokine in our assay. 
Altogether, our findings demonstrate that B cells from a  majority of CLL, as 
well as normal B cells, are susceptible to IL-2. The role of IL-2 in B cell growth, 
so  far,  has  been  controversial.  For  instance,  IL-2,  together  with  two  other 
lympbokines, was needed for mouse B cell proliferation and differentiation (13); 
human  B  cells preactivated  by SAC  were shown  to proliferate  in  response  to 
purified IL-2, in accordance with our results (12). On the other hand, it has been 
reported (14,  15) that absorption of IL-2 from T  cell-conditioned medium did 
not modify the proliferative response of activated normal B cells. 
Although CLL B cells can differentiate, with T  cell help, into plasma cells, we 
did not observe such an effect with IL-2. When IL-2-reponsive cells (four cases) 
were studied 3-12 d after SAC or anti-u preactivation, the majority of cells were 
large immunoblasts devoid of cytoplasmic Ig. 
These results raise important  issues on the possible in vivo role of physiologic 
lymphokines such as IL-2 on the growth of the leukemic clone. It is worth noting 
that in one case, cells were responsive to IL-2 without any preactivation; in other 
instances,  it is conceivable that antiidiotypic antibodies directed against surface 
Ig may trigger expression of IL-2 receptors, thus leading to possible regulation 
or expansion of the leukemic B cell clone by IL-2. 
Summary 
The proliferative responses of purified leukemic human  B cells from nine  B 
cell chronic lymphocytic leukemias to recombinant interleukin  2 (IL-2), sponta- 
neously,  and  after preactivation  by Staphylococcus aureus  Cowan  I  (SAC) or 
anti-u antibodies were studied. Three patterns of response were observed: (a) no 
response (three cases); (b) a  moderate spontaneous response enhanced by anti-u 
(one case); (c) a  high proliferative response after preactivation by anti-u and/or 
SAC (five cases). IL-2 could also trigger normal B cells, purified from spleen, to 
proliferative after preactivation by anti-u or SAC. These results provide evidence 
that IL-2 is a lymphokine that acts physiologically on both B and T  cells. 
Received for publicat¢on 17 October 1984 and in revised form 27 February 1985. 
References 
1.  Preud'homme, J. L., and M. Seligmann.  1972. Surface bound immunoglobulins  as a 
cell marker in human lymphoproliferative diseases. Blood. 40:777. 1230  LANTZ  ET  AL.  BRIEF  DEFINITIVE REPORT 
2.  Guglielmi,  P., J.  L.  Preud'homme,  R.  Ciorbaru-Barot,  and  M.  Seligmann.  1982. 
Mitogen-induced maturation of chronic lymphocytic leukemia B lymphocytes.  J. Clin. 
Immunol.  2:186. 
3.  Robert, K. H., A. G. Bird, and E. M611er, 1979. Mitogen-induced differentiation of 
human CLL lymphocytes to antibody-secreting cells. Scand. J. Immunol.  10:447. 
4.  T6tterman,  T.  H.,  K.  Nilsson,  and  C.  Sundstr6m.  1980.  Phorbol  ester-induced 
differentiation of chronic lymphocytic leukaemia cells. Nature (Lond.). 288:176. 
5.  Yoshizaki,  K.,  T.  Nakagawa,  T.  Kaieda,  A.  Muraguchi,  Y.  Yamamura,  and  T. 
Kishimoto. 1982. Induction of proliferation and Ig production in human B leukemic 
cells by anti-immunoglobulins and T  cell factors. J. Immunol.  128:1296. 
6.  Fu, S. M., N. Chiorazzi, H. G. KunkeI,J. P. Haiper, and S. R. Harris. 1978. Induction 
of in  vitro  differentiation  and  immunoglobulin  synthesis  of human  leukemic  B 
lymphocytes.J. Exp. Med.  148:1570. 
7.  Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T cell growth factor: parameters 
of production and a quantitative microassay for activity. J. Immunol.  120:2027. 
8.  Bertoglio, J., N. Boisson. 1982. First French Workshop on Human IL2: Joint report. 
Lymphokine  Res.  1 : 121. 
9.  Muraguchi,  A., and A. S.  Fauci.  1982.  Proliferative responses of normal human B 
lymphocytes, development of an assay system for human B cell growth factor (BCGF). 
J. Immunol.  129:1104. 
10.  Muraguchi, A.,J. L. Butler, J. H. Kehrl, and A. S. Fauci. 1983. Differential sensitivity 
of  human  B  cell  subsets  to  activation  signals  delivered  by  anti-~  antibody  and 
proliferative signals delivered by a  monoclonal B cell  growth  factor. J.  Exp.  Med. 
157:530. 
11.  Kehrl, J. H., A. Muraguchi, and A. S. Fauci.  1984. Human B cell activation and cell 
cycle progression: stimulation with anti-u and Staphylococcus aureus Cowan strain I. 
Eur. J. Immunol.  14:115. 
12.  Tsudo,  M.,  T.  Uchiyama,  and  H.  Uchino.  1984.  Expression  of Tac  antigen  on 
activated normal human B cells.J. Exp. Med.  160:612. 
13.  Roehm, N. W., P. Marrack, and J. W. Kappler.  1983. Helper signals in the plaque- 
forming cell response to protein-bound haptens. J. Exp. Med.  158:317. 
14.  Muraguchi, A., T. Kasahara, J. J. Oppenheim, and A. S. Fauci.  1982. B cell growth 
factor and  T  cell  growth  factor produced  by mitogen-stimulated  normal  human 
peripheral blood T  lymphocytes are distinct molecules. J. lmmunol.  12:2486. 
15.  Howard, M., J. Farrar, M. Hilfiker, B. Johnson, K. Takatsu, T. Hamaoka, and W. E. 
Paul.  1982.  Identification of a  T  cell-derived B  cell growth  factor distinct  from 
interleukin 2. J. Exp. Med.  155:914. 